Canada markets closed

Bellerophon Therapeutics, Inc. (BLPH)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.05620.0000 (0.00%)
At close: 09:30AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.0562
Open0.0562
Bid0.0000 x 800
Ask0.0000 x 1400
Day's Range0.0562 - 0.0562
52 Week Range0.0290 - 11.1500
Volume506
Avg. Volume33,054
Market Cap687,477
Beta (5Y Monthly)0.69
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease

    Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity INOpulse® was safe and well-tolerated, consistent with the overall safety profile demonstrated in Phase 2 and other INOpulse® programs in PH-COPD and PH-SarcoidosisCompany to host conference call and webcast with slides today at 8:30 AM ET WARREN, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeu

  • GlobeNewswire

    Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results

    Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse®; Pivotal Top-line Data Expected in Mid-2023 WARREN, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2023. “We are pleased with the prog